# Carboplatin and Bevacizumab for Recurrent Ependymoma

> **NCT01295944** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 35 (actual)

## Conditions studied

- Ependymoma
- Anaplastic Ependymoma

## Interventions

- **DRUG:** Carboplatin
- **DRUG:** Bevacizumab

## Key facts

- **NCT ID:** NCT01295944
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-04-27
- **Primary completion:** 2020-09-23
- **Final completion:** 2021-05-14
- **Target enrollment:** 35 (ACTUAL)
- **Last updated:** 2025-08-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01295944

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01295944, "Carboplatin and Bevacizumab for Recurrent Ependymoma". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT01295944. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*